Page 7 - Revascularization Device News Today

Comerica Bank lifted its stake in Penumbra, Inc. (NYSE:PEN – Get Rating) by 2.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,072 shares of the company’s stock after acquiring an additional 320 shares during the quarter. Comerica Bank’s holdings in Penumbra […]

Adynxx (OTCMKTS:ADYX – Get Rating) and Penumbra (NYSE:PEN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Volatility and Risk Adynxx has a beta of 2.32, indicating that its […]

Penumbra (NYSE:PEN – Get Rating) and DarioHealth (NASDAQ:DRIO – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations. Insider & Institutional Ownership 80.5% of Penumbra shares are owned by institutional […]

Wall Street analysts expect Penumbra, Inc. (NYSE:PEN – Get Rating) to post sales of $206.27 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Penumbra’s earnings, with estimates ranging from $205.60 million to $206.96 million. Penumbra reported sales of $184.26 million in the same quarter last year, […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Penumbra (NYSE:PEN – Get Rating) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses neuro […]

Penumbra (NYSE:PEN – Get Rating) is scheduled to release its earnings data after the market closes on Tuesday, May 3rd. Analysts expect Penumbra to post earnings of $0.07 per share for the quarter. Penumbra has set its FY 2022 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using […]

Penumbra (NYSE:PEN – Get Rating) and Alpha Tau Medical (NASDAQ:DRTS – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Insider and Institutional Ownership 79.4% of Penumbra shares are held […]

Penumbra (NYSE:PEN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses […]

Equities analysts expect Penumbra, Inc. (NYSE:PEN – Get Rating) to post earnings per share (EPS) of $0.07 for the current quarter, Zacks reports. Three analysts have made estimates for Penumbra’s earnings. The lowest EPS estimate is $0.06 and the highest is $0.08. Penumbra posted earnings per share of $0.27 in the same quarter last year, […]